Henry Schein (HSIC) posted solid third-quarter 2023 sales growth and non-GAAP EPS growth despite continued lower sales of PPE products and COVID-19 test kits. In addition, the company’s long-term outlook appears bright, driven by sustained demand for its healthcare solutions and strategic investments. So, is it worth adding this medical stock to your watchlist? Read more to find out…
Henry Schein (HSIC) posted solid third-quarter 2023 sales growth and non-GAAP EPS growth despite continued lower sales of PPE products and COVID-19 test kits. In addition, the company’s long-term outlook appears bright, driven by sustained demand for its healthcare solutions and strategic investments. So, is it worth adding this medical stock to your watchlist? Read more to find out…
